Scientific Founder

The Scientific Founders at Epsilogen are the driving force behind the company’s groundbreaking research and scientific innovation in the field of immunoglobulin E (IgE) antibody-based cancer therapies. With their exceptional expertise and deep understanding of IgE biology, these esteemed scientists have laid the foundation for Epsilogen’s pioneering work in revolutionizing cancer treatment.

Drawing on their extensive knowledge and years of experience, the Scientific Founders have made significant contributions to the understanding of IgE’s unique properties and its potential applications in targeting solid tumors. Their cutting-edge research has shed light on the enhanced potency, improved tumor access, and prolonged tissue half-life of IgE, making it a promising avenue for combating cancer.